Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. entered into a definitive agreement for a registered direct offering raising approximately $10.5 million in gross proceeds. The company will sell 1,666,679 shares of common stock at $3.90 per share and issue pre-funded warrants to purchase up to 1,025,654 shares at $3.8999 per warrant, with a nominal exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable but subject to a 9.99% beneficial ownership cap. Q32 Bio plans to use the net proceeds, along with existing cash and securities, for working capital, including research, clinical development and commercialization efforts, and to advance its alopecia areata candidate bempikibart into future clinical trials.
Q32 Bio is offering 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares, raising approximately $10.5 million before expenses at $3.90 per share. The pre-funded warrants are priced at $3.8999 and carry a nominal exercise price of $0.0001 per share.
Net proceeds of about $10.3 million will fund working capital, research and clinical development, particularly advancing lead antibody bempikibart for alopecia areata and future trials. The company highlights that investors will experience immediate and substantial dilution, and future equity financings could further dilute existing holders.
Pre-funded warrants are immediately exercisable, do not trade on any exchange and have beneficial ownership limits, generally capped at up to 19.99% (with lower 4.99% or 9.99% options), which can restrict exercises for larger holders. Q32 Bio remains a smaller reporting company with reduced disclosure requirements and emphasizes the high risks typical of early-stage biotechnology development.
Pfizer Inc. has filed an amended Schedule 13G reporting a passive minority stake in Q32 Bio Inc. Pfizer reports beneficial ownership of 277,777 shares of Q32 Bio common stock, representing 2.3% of the outstanding shares.
The ownership percentage is based on 12,304,352 Q32 Bio common shares outstanding as of November 1, 2025, as disclosed by the company. Pfizer notes that its holdings trace back to shares it previously reported in Homology Medicines, Inc., which merged into Q32 Bio with Q32 Bio as the surviving entity.
Pfizer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Q32 Bio, confirming this is a passive investment position below the 5% threshold.
Q32 Bio director Kathleen LaPorte reported a new stock option grant. On 01/15/2026, she received a stock option to buy 23,272 shares of Q32 Bio Inc. common stock with a $3.60 exercise price, under the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy.
The option vests in four equal quarterly installments on the last day of each calendar quarter, as long as she continues serving as a director. LaPorte elected to receive stock options instead of cash retainer fees, and the company notes this award was initially omitted from prior reports due to administrative oversight.
Q32 Bio Inc. director David S. Grayzel reported a grant of stock options on January 15, 2026 under the company’s 2024 Stock Option and Incentive Plan and non-employee director compensation policy. The award covers 16,363 options with an exercise price of $2.75 per share.
The options vest in four equal quarterly installments on the last day of each calendar quarter, conditioned on his continued service, and were elected in lieu of cash retainer fees. The filing notes the grant was initially omitted due to administrative oversight. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. reported that director Sven Ante Lundberg received a grant of stock options on January 15, 2026. The award covers 20,363 stock options to buy Q32 Bio common stock at an exercise price of $2.75 per share.
The options were granted under the company’s 2024 Stock Option and Incentive Plan and its non-employee director compensation policy, reflecting Lundberg’s election to receive options instead of cash retainer fees. The grant vests in four equal quarterly installments, each at the end of a calendar quarter, conditioned on continued board service. The filing notes the award was initially not reported due to administrative oversight.
Q32 Bio (QTTB) reported third‑quarter 2025 results showing sharply lower operating spend and a narrower loss, alongside a reduced cash balance and an equity deficit. Cash and cash equivalents were $49.0 million as of September 30, 2025, down from $78.0 million at year‑end. Total assets were $57.8 million against total liabilities of $76.2 million, resulting in stockholders’ equity (deficit) of $(18.4) million.
Quarterly net loss was $7.4 million versus $17.6 million a year ago as research and development fell to $3.6 million from $14.3 million, with general and administrative at $4.0 million. For the nine months, net loss totaled $27.9 million, and operating cash outflow was $27.4 million. The company expects its cash to fund operations for at least one year from the financial statement issuance date. Management executed a February 2025 restructuring to prioritize bempikibart in AA, discontinued the Phase 2 ADX‑097 renal basket trial, and recorded $0.9 million of severance costs. The company also completed the sale of its 10% OXB (US) LLC interest for $2.5 million and eliminated the related CVR liability by quarter end.
Q32 Bio Inc. reported that it announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The company furnished a press release as Exhibit 99.1 to an Item 2.02 current report.
The information in the report, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. Q32 Bio’s common stock trades on the Nasdaq Global Market under the symbol QTTB.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. The director was awarded 53,521 stock options at an exercise price of $2.80 per share on 10/23/2025, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual meeting of stockholders, subject to continued service. Following the transaction, the director beneficially owns 53,521 derivative securities, held directly.
Q32 Bio (QTTB) reported a director’s stock option grant on a Form 4. On 10/23/2025, the director acquired 53,521 stock options (Code A) with an exercise price of $2.80 per share, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual stockholder meeting, contingent on continued service. Following this transaction, the director beneficially owns 53,521 derivative securities, held directly. The price of the derivative security was listed as $0.00.